华特达因(000915) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥605,516,557.27, representing a 23.74% increase compared to ¥489,326,504.49 in the same period last year[4] - Net profit attributable to shareholders for Q1 2022 was ¥156,021,080.23, up 43.18% from ¥108,966,290.01 in Q1 2021[4] - Basic earnings per share for Q1 2022 were ¥0.67, a 42.55% increase from ¥0.47 in Q1 2021[4] - Operating profit for Q1 2022 was ¥345,797,233.28, up 42.0% from ¥243,874,893.81 in the same period last year[22] - The net profit after deducting non-recurring gains and losses was ¥155,708,478.77, which is a 45.80% increase from ¥106,799,559.07 in the same period last year[4] Cash Flow - The net cash flow from operating activities increased by 102.02%, reaching ¥276,299,060.18 compared to ¥136,767,795.21 in the previous year[4] - The net cash flow from operating activities for Q1 2022 was ¥276,299,060.18, a significant increase of 102.3% compared to ¥136,767,795.21 in the same period last year[26] - Cash received from sales of goods and services was ¥670,887,451.35, up from ¥579,666,292.74 in the previous year, reflecting a growth of 15.7%[26] - Cash paid for purchasing goods and services decreased to ¥52,690,791.18 from ¥120,335,520.50, a reduction of 56.2%[26] - The cash flow from operating activities totaled ¥687,190,815.22, compared to ¥593,516,866.95 in the same period last year, marking an increase of 15.8%[26] Assets and Liabilities - Total assets at the end of Q1 2022 amounted to ¥4,317,462,526.81, reflecting a 9.71% increase from ¥3,935,426,876.64 at the end of the previous year[4] - Total liabilities rose to ¥623,824,218.28, compared to ¥536,028,235.88, marking an increase of 16.3%[22] - Total current assets reached ¥2,798,260,444.65, up from ¥2,411,163,790.74 at the beginning of the year[16] - Cash and cash equivalents amounted to ¥1,540,661,180.06, an increase from ¥1,223,433,930.52 at the beginning of the year[16] Shareholder Information - Total number of common shareholders at the end of the reporting period was 13,573[12] - The company has a significant shareholder, Shandong Huate Holding Group Co., Ltd., holding 22.00% of shares[12] - The top ten shareholders include various institutional investors, indicating a diverse ownership structure[12] - The company has not disclosed any related party relationships among its major shareholders[15] Research and Development - Research and development expenses for Q1 2022 totaled ¥12,769,669.95, a rise from ¥11,043,104.80 in Q1 2021[22] Strategic Outlook - The increase in revenue was primarily driven by the growth in profits from the subsidiary, Dain Pharmaceutical[7] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[22] - There are no significant new strategies or product developments mentioned in the report[18] Non-Recurring Items - The company reported a total of ¥312,601.46 in non-recurring gains for the period[6] - The company did not undergo any retrospective adjustments or restatements of previous years' financial data[4]